Profile data is unavailable for this security.
About the company
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.
- Revenue in USD (TTM)77.68m
- Net income in USD843.00k
- Incorporated2014
- Employees58.00
- LocationJourney Medical Corp9237 E Via De Ventura Blvd.Suite 105, Suite 105SCOTTSDALE 85258United StatesUSA
- Phone+1 (480) 434-6670
- Fax+1 (302) 531-3150
- Websitehttps://journeymedicalcorp.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lexaria Bioscience Corp | 411.01k | -4.85m | 51.54m | 5.00 | -- | 5.09 | -- | 125.40 | -0.4455 | -0.4455 | 0.0408 | 0.6403 | 0.0539 | -- | 2.16 | 82,202.00 | -63.85 | -95.67 | -65.93 | -96.58 | 98.83 | 76.98 | -1,185.15 | -1,612.76 | -- | -64.96 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 57.53m | 134.00 | 4.86 | 0.2302 | 1.76 | 0.2234 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
| Qilian International Holding Group Ltd | 29.87m | -7.86m | 58.25m | 298.00 | -- | 1.33 | -- | 1.95 | -1.10 | -1.10 | 4.18 | 6.07 | 0.5237 | 3.73 | 25.96 | 100,236.40 | -14.43 | 2.71 | -17.01 | 3.86 | 2.92 | 11.66 | -27.56 | 2.72 | 6.06 | -0.7527 | 0.00 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| SCYNEXIS Inc | 9.67m | -35.39m | 60.19m | 29.00 | -- | 0.9965 | -- | 6.23 | -0.735 | -0.735 | 0.2005 | 1.60 | 0.0736 | -- | 0.7011 | 333,344.80 | -26.95 | -30.02 | -31.99 | -36.35 | -55.82 | -- | -366.09 | -86.76 | -- | -- | 0.1747 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| United-Guardian, Inc. | 12.31m | 3.25m | 66.80m | 25.00 | 20.58 | 5.51 | 19.94 | 5.43 | 0.7065 | 0.7065 | 2.68 | 2.64 | 0.9575 | 4.12 | 7.65 | 492,387.20 | 25.25 | 29.84 | 28.67 | 34.39 | 50.66 | 55.31 | 26.37 | 28.79 | 6.99 | -- | 0.00 | 97.37 | -14.28 | -4.14 | 0.4616 | -9.92 | 17.19 | -19.73 |
| Journey Medical Corp | 77.68m | 843.00k | 74.37m | 58.00 | 50.30 | 8.95 | 18.14 | 0.9574 | -0.0131 | -0.0131 | 3.91 | 0.5642 | 1.15 | 2.36 | 5.71 | 1,339,328.00 | 1.25 | -- | 5.17 | -- | 66.79 | -- | 1.09 | -- | 1.08 | 2.00 | 0.6682 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -29.10m | 74.41m | 43.00 | -- | 7.75 | -- | -- | -0.5806 | -0.5806 | 0.00 | 0.1562 | 0.00 | -- | -- | -- | -100.88 | -70.19 | -124.78 | -78.31 | -- | -- | -- | -15,434.15 | 0.1793 | -36.79 | 0.5517 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Verrica Pharmaceuticals Inc | 13.91m | -86.93m | 75.52m | 100.00 | -- | -- | -- | 5.43 | -1.88 | -1.88 | 0.3001 | -0.3133 | 0.2436 | -- | 2.68 | 139,080.00 | -152.23 | -55.75 | -196.62 | -78.33 | 84.02 | -- | -625.06 | -754.94 | 2.23 | -12.96 | 1.42 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Cellectar Biosciences Inc | 0.00 | -50.98m | 75.64m | 20.00 | -- | 7.70 | -- | -- | -3.17 | -3.17 | 0.00 | 0.789 | 0.00 | -- | -- | 0.00 | -176.58 | -83.69 | -295.36 | -99.80 | -- | -- | -- | -- | -- | -4.81 | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Marinus Pharmaceuticals Inc | 30.26m | -149.24m | 85.38m | 165.00 | -- | -- | -- | 2.82 | -2.66 | -2.66 | 0.5391 | -0.8614 | 0.21 | 0.7508 | 6.98 | 183,412.10 | -103.54 | -49.64 | -131.60 | -57.76 | 90.64 | -- | -493.14 | -518.96 | 2.15 | -11.80 | 6.10 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| I-Mab ADR | -100.00bn | -100.00bn | 88.16m | 220.00 | -- | 0.3751 | -- | -- | -- | -- | -- | 2.91 | -- | -- | -- | -- | -- | -35.51 | -- | -41.43 | -- | -- | -- | -509.54 | -- | -- | 0.00 | -- | 111.86 | -13.65 | 44.45 | -- | -5.95 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 88.22m | 35.00 | 391.37 | 348.44 | -- | 35.38 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 23.10m | -27.21m | 92.34m | 176.00 | -- | 10.24 | -- | 4.00 | -2.03 | -2.03 | 1.72 | 0.6731 | 0.3577 | 0.8917 | 2.39 | 131,250.00 | -41.56 | -34.75 | -62.38 | -46.91 | 56.81 | 55.98 | -116.17 | -153.72 | 2.36 | -- | 0.6718 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
Data as of Sep 18 2024. Currency figures normalised to Journey Medical Corp's reporting currency: US Dollar USD
12.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 305.61k | 2.08% |
| Cambridge Investment Research Advisors, Inc.as of 30 Jun 2024 | 294.95k | 2.00% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 264.03k | 1.79% |
| American Money Management Corp.as of 30 Jun 2024 | 180.00k | 1.22% |
| PVG Asset Management Corp.as of 30 Jun 2024 | 158.54k | 1.08% |
| Tang Capital Management LLCas of 30 Jun 2024 | 148.32k | 1.01% |
| Envestnet Asset Management, Inc.as of 30 Jun 2024 | 131.57k | 0.89% |
| Rosalind Advisors, Inc.as of 30 Jun 2024 | 114.13k | 0.78% |
| Geode Capital Management LLCas of 30 Jun 2024 | 95.55k | 0.65% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 94.40k | 0.64% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
